一分钟看懂
这是一项关于结直肠癌的III 期研究，登记的药物或干预包括Calderasib；Oxaliplatin；Leucovorin/levofolinate calcium；5-Fluorouracil；Cetuximab；Bevacizumab；Bevacizumab biosimilar，当前状态为招募中。登记地点显示中国合肥、北京、重庆、万州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Calderasib；Oxaliplatin；Leucovorin/levofolinate calcium；5-Fluorouracil；Cetuximab；Bevacizumab；Bevacizumab biosimilar · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Cancer Hospital ( Site 0803) · 合肥
- The Second Affiliated Hospital of Anhui Medical University ( Site 0813) · 合肥
- Peking Union Medical College Hospital ( Site 0824) · 北京
- Peking University First Hospital(Daxing Area) ( Site 0838) · 北京
- Chongqing University Cancer Hospital ( Site 0808) · 重庆
- Chongqing University Three Gorges Hospital ( Site 0837) · 万州
- Fujian Cancer Hospital ( Site 0807) · 福州
- The First Affiliated Hospital of Xiamen University ( Site 0806) · 厦门
- Zhongshan Hospital Affiliated to Xiamen University ( Site 1902) · 厦门
- Sun Yat-Sen University Cancer Center ( Site 0800) · 广州
- Southern Medical University Nanfang Hospital ( Site 0812) · 广州
- The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 0828) · 广州
- The University of Hong Kong - Shenzhen Hospital ( Site 1903) · 深圳
- Guangxi Medical University Affiliated Tumor Hospital ( Site 0804) · 南宁
- Harbin Medical University Cancer Hospital ( Site 0847) · 哈尔滨
- Henan Cancer Hospital ( Site 0822) · 郑州
- Tongji Hospital Tongji Medical,Science & Technology ( Site 0839) · 武汉
- Hubei Cancer Hospital ( Site 0814) · 武汉
- Hunan Cancer Hospital ( Site 0815) · 长沙
- The Third Xiangya Hospital of Central South University ( Site 0834) · 长沙
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0825) · 南京
- The First Affiliated Hospital of Nanchang University ( Site 0826) · 南昌
- Jilin Cancer Hospital ( Site 0830) · 长春
- The First Affiliated Hospital of Xi an Jiaotong University ( Site 0802) · 西安
- Jinan Central Hospital ( Site 0817) · 济南
- Shandong Cancer Hospital ( Site 1901) · 济南
- Zhongshan Hospital of Fudan University ( Site 0832) · 上海
- Fudan University Shanghai Cancer Center ( Site 0816) · 上海
- Shanghai Renji Hospital Affiliated to Jiao Tong University ( Site 1906) · 上海
- First Affiliated Hospital of Shanxi Medical University ( Site 0843) · 太原
- West China Hospital, Sichuan University ( Site 0805) · 成都
- Sichuan Cancer hospital. ( Site 0831) · 成都
- First Affiliated Hospital of Kunming Medical University ( Site 0845) · 昆明
- The Second Affiliated Hospital Zhejiang University School of Medicine ( Site 0801) · 杭州
- Zhejiang Cancer Hospital ( Site 0821) · 杭州
- The First Affiliated Hospital of Wenzhou Medical University ( Site 0840) · 温州
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Has a histologically confirmed diagnosis of locally advanced unresectable or metastatic (unresectable Stage III or Stage IV as defined by American Joint Committee on Cancer \[AJCC\] eighth edition) colorectal adenocarcinoma
- * Part 2 only: Has not received systemic anticancer therapy for locally advanced unresectable or metastatic colorectal cancer; an exception is permitted for 1-2 cycles of FOLFOX or 1 cycle of CAPOX as optional chemotherapy before or during the screening period
- * Demonstrates presence of a Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation
- * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
- * Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load
- * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06997497；登记信息更新于 2026-09-14。